Net Income (Loss) Attributable to Parent of ArriVent BioPharma, Inc. from 31 Mar 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ArriVent BioPharma, Inc. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Mar 2023 to 31 Dec 2025.
  • ArriVent BioPharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Dec 2025 was $35,544,000, a 72% decline year-over-year.
  • ArriVent BioPharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Dec 2025 was $166,308,000, a 107% decline year-over-year.
  • ArriVent BioPharma, Inc. annual Net Income (Loss) Attributable to Parent for 2025 was $166,308,000, a 107% decline from 2024.
  • ArriVent BioPharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $80,488,000, a 16% decline from 2023.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

ArriVent BioPharma, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $166,308,000 $35,544,000 -$14,911,000 -72% 01 Oct 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $151,397,000 $34,978,000 -$14,414,000 -70% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $136,983,000 $31,399,000 -$9,525,000 -44% 01 Apr 2025 30 Jun 2025 10-Q 10 Nov 2025 2025 Q3
Q1 2025 $127,458,000 $64,387,000 -$46,970,000 -270% 01 Jan 2025 31 Mar 2025 10-Q 10 Nov 2025 2025 Q3
Q4 2024 $80,488,000 $20,633,000 +$560,000 +2.6% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $81,048,000 $20,564,000 -$6,163,000 -43% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $74,885,000 $21,874,000 -$307,000 -1.4% 01 Apr 2024 30 Jun 2024 10-Q 10 Nov 2025 2025 Q3
Q1 2024 $74,578,000 $17,417,000 -$5,245,000 -43% 01 Jan 2024 31 Mar 2024 10-Q 10 Nov 2025 2025 Q3
Q4 2023 $69,333,000 $21,193,000 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $14,401,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $21,567,000 01 Apr 2023 30 Jun 2023 10-Q 14 Nov 2024 2024 Q3
Q1 2023 $12,172,000 01 Jan 2023 31 Mar 2023 10-Q 14 Nov 2024 2024 Q3

ArriVent BioPharma, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $166,308,000 -$85,820,000 -107% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $80,488,000 -$11,155,000 -16% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $69,333,000 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.